RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Rating of “Hold” from Analysts

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have received a consensus recommendation of “Hold” from the nine ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $4.00.

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of RAPT Therapeutics in a research report on Monday, March 10th.

Institutional Trading of RAPT Therapeutics

Large investors have recently made changes to their positions in the company. Picton Mahoney Asset Management lifted its position in shares of RAPT Therapeutics by 994.4% in the fourth quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock worth $26,000 after purchasing an additional 14,697 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock worth $34,000 after buying an additional 25,130 shares during the period. Readystate Asset Management LP bought a new position in shares of RAPT Therapeutics during the third quarter worth approximately $36,000. Barclays PLC increased its position in RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after buying an additional 29,195 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in RAPT Therapeutics during the fourth quarter worth about $63,000. Institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Stock Down 7.1 %

NASDAQ RAPT opened at $1.45 on Thursday. The business has a 50 day moving average price of $1.19 and a two-hundred day moving average price of $1.47. The stock has a market cap of $191.41 million, a PE ratio of -0.52 and a beta of -0.31. RAPT Therapeutics has a fifty-two week low of $0.79 and a fifty-two week high of $9.65.

RAPT Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.69). Sell-side analysts anticipate that RAPT Therapeutics will post -2.14 EPS for the current fiscal year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.